Dual immunological blockade in the treatment of metastatic non-small cell lung cancer: reality and perspectives
Nowadays immunotherapy is a crucial option in the treatment of non-small cell lung cancer. There are a lot of actual options of the first-line therapy for the patients with metastatic lung cancer, including dual immunological blockade of PD-1/PD-L1 and CTLA-4 pathways. This review is an attempt to c...
Guardado en:
| Autores principales: | , , , |
|---|---|
| Formato: | article |
| Lenguaje: | RU |
| Publicado: |
IP Habib O.N.
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/a92e51c914374d90b0dcf921ac158329 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:a92e51c914374d90b0dcf921ac158329 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:a92e51c914374d90b0dcf921ac1583292021-11-30T16:55:01ZDual immunological blockade in the treatment of metastatic non-small cell lung cancer: reality and perspectives1815-14341815-144210.26442/18151434.2021.3.201189https://doaj.org/article/a92e51c914374d90b0dcf921ac1583292021-11-01T00:00:00Zhttps://modernonco.orscience.ru/1815-1434/article/viewFile/83040/pdfhttps://doaj.org/toc/1815-1434https://doaj.org/toc/1815-1442Nowadays immunotherapy is a crucial option in the treatment of non-small cell lung cancer. There are a lot of actual options of the first-line therapy for the patients with metastatic lung cancer, including dual immunological blockade of PD-1/PD-L1 and CTLA-4 pathways. This review is an attempt to clarify the place of dual immunological blockade now and in the future. The scientific rationale for dual immunotherapy is a possible synergy and overcome resistance to single-drug therapy. The review collected information from open sources, both current studies with dual immunological blockade, and already obtained results of the trials for nivolumab and ipilimumab, tremelimumab and durvalumab, and other combinations for the treatment of patients with metastatic non-small cell lung cancer. This approach is promising for the possible overcoming of resistance to monoimmunotherapy with anti-PD1/PD-L1 antibodies, especially in the population with low and negative PD-L1 status.Denis I. YudinKonstantin K. LaktionovLiudmila V. LaktionovaValeriy V. BrederIP Habib O.N.articledual immunotherapymetastatic lung cancernon-small cell lung canceranti-pd1anti-pd-l1anti-ctla-4anti-pd1/ctla-4Neoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282RUСовременная онкология, Vol 23, Iss 3, Pp 428-435 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
RU |
| topic |
dual immunotherapy metastatic lung cancer non-small cell lung cancer anti-pd1 anti-pd-l1 anti-ctla-4 anti-pd1/ctla-4 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 |
| spellingShingle |
dual immunotherapy metastatic lung cancer non-small cell lung cancer anti-pd1 anti-pd-l1 anti-ctla-4 anti-pd1/ctla-4 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Denis I. Yudin Konstantin K. Laktionov Liudmila V. Laktionova Valeriy V. Breder Dual immunological blockade in the treatment of metastatic non-small cell lung cancer: reality and perspectives |
| description |
Nowadays immunotherapy is a crucial option in the treatment of non-small cell lung cancer. There are a lot of actual options of the first-line therapy for the patients with metastatic lung cancer, including dual immunological blockade of PD-1/PD-L1 and CTLA-4 pathways. This review is an attempt to clarify the place of dual immunological blockade now and in the future. The scientific rationale for dual immunotherapy is a possible synergy and overcome resistance to single-drug therapy. The review collected information from open sources, both current studies with dual immunological blockade, and already obtained results of the trials for nivolumab and ipilimumab, tremelimumab and durvalumab, and other combinations for the treatment of patients with metastatic non-small cell lung cancer. This approach is promising for the possible overcoming of resistance to monoimmunotherapy with anti-PD1/PD-L1 antibodies, especially in the population with low and negative PD-L1 status. |
| format |
article |
| author |
Denis I. Yudin Konstantin K. Laktionov Liudmila V. Laktionova Valeriy V. Breder |
| author_facet |
Denis I. Yudin Konstantin K. Laktionov Liudmila V. Laktionova Valeriy V. Breder |
| author_sort |
Denis I. Yudin |
| title |
Dual immunological blockade in the treatment of metastatic non-small cell lung cancer: reality and perspectives |
| title_short |
Dual immunological blockade in the treatment of metastatic non-small cell lung cancer: reality and perspectives |
| title_full |
Dual immunological blockade in the treatment of metastatic non-small cell lung cancer: reality and perspectives |
| title_fullStr |
Dual immunological blockade in the treatment of metastatic non-small cell lung cancer: reality and perspectives |
| title_full_unstemmed |
Dual immunological blockade in the treatment of metastatic non-small cell lung cancer: reality and perspectives |
| title_sort |
dual immunological blockade in the treatment of metastatic non-small cell lung cancer: reality and perspectives |
| publisher |
IP Habib O.N. |
| publishDate |
2021 |
| url |
https://doaj.org/article/a92e51c914374d90b0dcf921ac158329 |
| work_keys_str_mv |
AT denisiyudin dualimmunologicalblockadeinthetreatmentofmetastaticnonsmallcelllungcancerrealityandperspectives AT konstantinklaktionov dualimmunologicalblockadeinthetreatmentofmetastaticnonsmallcelllungcancerrealityandperspectives AT liudmilavlaktionova dualimmunologicalblockadeinthetreatmentofmetastaticnonsmallcelllungcancerrealityandperspectives AT valeriyvbreder dualimmunologicalblockadeinthetreatmentofmetastaticnonsmallcelllungcancerrealityandperspectives |
| _version_ |
1718406464179011584 |